Inovio Pharmaceuticals Inc (INO)Shares Soar on Possible Zika Vaccine By Year’s End

Share

Today it was announced that a pharmaceutical consortium, which includes Inovio Pharmaceuticals Inc (NASDAQ:INO) are making major headway on a possible vaccine to combat the rapidly spreading Zika virus. The virus, which may be responsible for birth defects, if the mother is infected during early pregnancy, has been spreading rapidly over the last several months, and now experts fear it could reach North America by Summer, or even sooner.

A Canadian scientist named Gary Kobinger told Reuters this morning that a vaccine for the virus may be ready for human testing as early as August and could be approved for emergency use in October or November if all goes well.

“The first thing is to be ready for the worst,” Kobinger said. “This vaccine is easy to produce. It could be cranked to very high levels in a really short time.”

This is great news for mothers-to-be as the virus often goes unnoticed in human beings and seldom has any major effects on their health, but is believed to cause microcephaly in newborns.

Inovio Pharmaceuticals Inc (NASDAQ:INO) shares are up $0.34 or 5.88% in the pre-market this morning on the news.The stock increased 7.64% or $0.41 during the last trading session, hitting $5.78. About 174,729 shares traded hands. INO has declined 34.32% since June 24, 2015 and is downtrending. It has underperformed the S&P500 by 25.45%.

Inovio Pharmaceuticals, Inc. is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company has a market cap of $387.27 million. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. It currently has negative earnings. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.

#focuskw=’Inovio Pharmaceuticals Inc (NASDAQ:INO)’##metadesc=’Today it was announced that a pharmaceutical consortium, which includes Inovio Pharmaceuticals Inc (NASDAQ:INO) are making major headway on a possible vaccine to combat the rapidly spreading Zika virus. The virus, which may be responsible for birth defects, if the mother is infected during early pregnancy, has been spreading rapidly over the last several months, and now experts fear it could reach North America by Summer, or even sooner.A Canadian scientist named Gary Kobinger told Reuters this morning that a vaccine for the virus may be ready for human testing as early as August and could be approved for emergency use in October or November if all goes well. “The first thing is to be ready for the worst,” Kobinger said. “This vaccine is easy to produce. It could be cranked to very high levels in a really short time.”This is great news for mothers-to-be as the virus often goes unnoticed in human beings and seldom has any major effects on their health, but is believed to cause microcephaly in newborns. Inovio Pharmaceuticals Inc (NASDAQ:INO) shares are up $0.34 or 5.88% in the pre-market this morning on the news.’##metarobot=’index’##newskw=’Zafgen Inc positive news,Zafgen Inc – (NASDAQ:ZFGN),NASDAQ:ZFGN Analyst rating analysis,Stock Analysis,Outlook and potential,ZFGN Price change and trend,ZFGN stock update’##sitemap=’include’##skipsocial##stockticker=’NASDAQ:INO’#

COMMENTS: